- Home
- LYFT vs BPMC Comparison
LYFT vs BPMC Comparison
Compare LYFT & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYFT
- BPMC
- Stock Information
- Founded
- LYFT 2007
- BPMC 2008
- Country
- LYFT United States
- BPMC United States
- Employees
- LYFT N/A
- BPMC N/A
- Industry
- LYFT Business Services
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- LYFT Consumer Discretionary
- BPMC Health Care
- Exchange
- LYFT Nasdaq
- BPMC Nasdaq
- Market Cap
- LYFT 6.3B
- BPMC 8.3B
- IPO Year
- LYFT 2019
- BPMC 2015
- Fundamental
- Price
- LYFT $16.07
- BPMC $128.40
- Analyst Decision
- LYFT Buy
- BPMC Buy
- Analyst Count
- LYFT 33
- BPMC 20
- Target Price
- LYFT $16.57
- BPMC $127.82
- AVG Volume (30 Days)
- LYFT 13.8M
- BPMC 3.5M
- Earning Date
- LYFT 08-06-2025
- BPMC 07-31-2025
- Dividend Yield
- LYFT N/A
- BPMC N/A
- EPS Growth
- LYFT N/A
- BPMC N/A
- EPS
- LYFT 0.14
- BPMC N/A
- Revenue
- LYFT $5,958,987,000.00
- BPMC $562,121,000.00
- Revenue This Year
- LYFT $14.15
- BPMC $44.46
- Revenue Next Year
- LYFT $12.81
- BPMC $32.78
- P/E Ratio
- LYFT $116.83
- BPMC N/A
- Revenue Growth
- LYFT 27.32
- BPMC 99.19
- 52 Week Low
- LYFT $8.93
- BPMC $73.04
- 52 Week High
- LYFT $19.07
- BPMC $128.52
- Technical
- Relative Strength Index (RSI)
- LYFT 58.12
- BPMC 74.70
- Support Level
- LYFT $15.58
- BPMC $128.06
- Resistance Level
- LYFT $16.46
- BPMC $128.52
- Average True Range (ATR)
- LYFT 0.54
- BPMC 0.27
- MACD
- LYFT 0.05
- BPMC -1.17
- Stochastic Oscillator
- LYFT 82.93
- BPMC 81.95
About LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.